Background Targeting the epidermal growth factor receptor (EGFR) pathway is an important approach for a variety of tumors. This study assessed the effect of cetuximab, an anti-EGFR monoclonal antibody, on three gastric cancer cell lines with different phenotypes in vitro and in a therapeutic orthotopic murine gastric cancer model. Methods Three human gastric cancer cell lines (AGS, MKN-45, NCI-N87) were evaluated for cell surface EGFR expression, and K-ras and BRAF mutations. In vitro, the effects of cetuximab, carboplatin, irinotecan, and docetaxel were investigated. Orthotopic tumors derived from MKN-45 and NCI-N87 were established in nude mice. After 4 weeks, the animals received cetuximab (1 mg/kg, weekly i.p.) or carboplatin (20 mg/kg, weekly i.p.), or both agents. The volume of the primary tumor and local and systemic tumor spread were determined at autopsy at 14 weeks. Tumor sections were immunostained for EGFR, as well as stained for CD31 to analyze microvessel density. Results Cell surface expression of EGFR was found only in AGS and NCI-N87 cells. AGS cells displayed a codon 12 K-ras mutation, and all three cell lines were BRAF wild-type. In vitro, cetuximab significantly reduced cell viability and proliferation only in EGFR-positive/K-ras wild-type NCI-N87 cells (-48%). In vivo, cetuximab in combination with carboplatin synergistically reduced tumor volume (-75%), dissemination (-63%), and vascularization (-47%) in NCI-N87 xenografts. Tumors derived from EGFR-negative MKN-45 cells were unaffected by cetuximab. Conclusions Cetuximab is effective in K-ras wild-type, EGFR-expressing gastric cancer cell lines and xenografts. In vivo, the combination of cetuximab with carboplatin displayed synergistic antitumor activity.
Introduction
Gastric cancer is one of the most common cancer types in the western world. The majority of stomach cancers are adenocarcinomas and they are associated with high mortality, as many patients present with locally advanced or metastatic disease, and treatment options are limited [1] . Apart from potentially curative surgery, chemotherapy as well as radiochemotherapy may be applied, but these modalities do not cure this disease [2] . Although recent efforts to improve the treatment of gastric cancer were promising, the outcome of advanced disease is still disappointing. Targeted agents are therefore being investigated to improve the clinical outcome of gastric cancer patients.
Epidermal growth factor receptor (EGFR) is involved in malignant transformation and tumor growth through the inhibition of apoptosis, cellular proliferation, promotion of angiogenesis, and metastasis. EGFR is abnormally activated in many types of epithelial tumors and this typically correlates with aggressive tumor growth, as well as with poor clinical outcome [3, 4] . In gastric cancer, EGFR is overexpressed in 18-91% of primary tumors [5] . Ligand binding of the EGFR activates the Ras/Raf/MAPK, STAT, and PI3K/AKT signaling pathways, which modulate cellular proliferation, angiogenesis, and survival. Cetuximab (C-225, Erbitux; Merck, Darmstadt, Germany) is a welldeveloped anti-EGFR monoclonal antibody and has been approved for clinical use in patients with metastatic colorectal cancer [6, 7] . It binds to the extracellular domain of EGFR with high affinity. It competitively blocks ligand binding and inhibits tyrosine kinase activation, resulting in receptor downregulation [8] . Apart from this competitive inhibition, cetuximab binding with EGFR might trigger internalization and destruction of the receptor [9] . Preclinical studies have shown that cetuximab is able to inhibit the growth of colon and pancreatic carcinoma cell lines and xenografts in animals [10, 11] . Available data also suggest a significant synergy with different cytotoxics and radiotherapy [12] [13] [14] . However, cetuximab is ineffective in patients with colorectal cancer bearing mutations in the K-ras gene, which is part of the EGFR signaling pathway [15, 16] . Mutated ras is constitutively activated, even when the EGFR is blocked. Together with K-ras, BRAF, a downstream gene of the RAS pathway, is also known to be somatically mutated in a number of human cancers, and BRAF mutations have been associated with resistance to EGFR-targeted antibody therapies [17] .
In the present study we therefore evaluated first the status of cell surface EGFR, K-ras, and BRAF mutations in the human gastric cancer cell lines AGS, MKN-45, and NCI-N87. Cell viability and proliferation was measured after treatment with cetuximab and different chemotherapeutics (carboplatin, irinotecan, and docetaxel) in vitro. According to the in vitro results we further investigated the therapeutic potential of cetuximab, either as monotherapy or combined with carboplatin, against MKN-45 (EGFRnegative, K-ras wild-type) and NCI-N87 (EGFR-positive, K-ras wild-type) xenografts in vivo, using an orthotopic model of human gastric carcinoma in nude mice. In addition we analyzed the microvessel density (MVD) of the orthotopic tumors by immunohistochemistry, as EGFR blockade with cetuximab may also inhibit angiogenesis [18] .
Materials and methods

Cell lines and culture conditions
The gastric adenocarcinoma cell lines AGS (poorly differentiated), MKN-45 (poorly differentiated), and NCI-N87 (well differentiated) were used for this study. The cell lines were obtained from the European Collection of Cell Cultures (ECACC; Salisbury, UK) and cultured in DMEM medium (AGS) or RPMI-1640 (MKN45, N87) (PAA Laboratories, Cölbe, Germany), supplemented with 10% fetal calf serum (FCS-Gold, PAA Laboratories), penicillin G (100 U/ml), streptomycin (100 lg/ml), and amphotericin B (0.25 mg/ml). Cells were incubated at 37°C in humidified air with 5% CO 2 . The medium was replaced three times a week, and cells were maintained by serial passaging after trypsinization with 0.1% trypsin.
Agents
The agents used were cetuximab (Erbitux Ò ; Merck), irinotecan (Campto Ò ; Pfizer, Berlin, Germany), carboplatin (GRY-Pharma, Kirchzarten, Germany), and docetaxel (Taxotere Ò ; Sanofi-Aventis, Berlin, Germany).
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total cellular RNA was extracted from cell cultures, using the NucleoSpin RNA II-Kit (Macherey & Nagel, Düren, Germany) according to the manufacturer's instructions, and resuspended in 50 ll of dimethylpyrocarbonate-treated water. The RNA concentration was determined using a BioPhotometer (Eppendorf Scientific, Hamburg, Germany). Total RNA (2 lg) was primed with an oligo(dT) oligonucleotide and reverse-transcribed with M-MLV reverse transcriptase (Promega, Mannheim, Germany) and dNTPs (Sigma-Aldrich, Seelze, Germany) according to the manufacturer's instructions. First-strand cDNA was amplified with transcript-specific oligonucleotides using Ready-Mix Taq PCR Reaction Mix (Sigma-Aldrich).
The primers (TIB MOLBIOL, Berlin, Germany) for the respective genes were designed as follows-EGFR, sense: 5 0 -TAC CTA AGG ATA GCA CCG C-3 0 ; antisense: 5 0 -TAC AAA GGA CTG CTG TTA ACC A-3 0 . b-actin, sense: 5 0 -TTC CTG GGC ATG GAG TCC TGT GG-3 0 ; antisense: 5 0 -CGC CTA GAA GCA TTT GCG GTG G-3 0 . The PCR products and a 1-kb DNA molecular weight marker were electrophoresed on a 1% agarose gel. The gel was then visualized and photographed under ultraviolet light.
Flow cytometry (fluorescence activated cell sorting [FACS])
Cells from the human gastric cancer cell lines AGS, MKN-45, and NCI-N87 were harvested with trypsin/ethylenediamine tetraacetic acid (EDTA) and washed three times with FACS buffer (phosphate-buffered saline [PBS] supplemented with 1% FCS) to completely remove culture medium. Then 2 9 10 5 cells were resuspended in 50 ll FACS buffer and blocked with 10 ll FcR (FcR blocking reagent; Miltenyi Biotec, Bergisch Gladbach, Germany) for 10 min at 4°C. The suspension was divided into two fractions and stained with 10 ll of a rat monoclonal EGFR antibody conjugated with APC (clone 423103; R&D System, Wiesbaden, Germany) or with 10 ll of an isotype control antibody conjugated with APC (rat IgG 2a ; R&D System). The labeled cells were then washed and the intensity of fluorescence was evaluated by a flow cytometer, FACSCalibur (BD Biosciences, San José, CA, USA) and the data were analyzed with the use of FlowJo 7.2.5 software (Tree Star, Ashland, OR, USA).
Mutation analysis
DNA isolation from the gastric cell lines AGS, MKN-45, and NCI-N87 was performed using the QiAmp DNA-Isolation Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
BRAF
BRAF mutations in codon 600 were evaluated. LightCycler (Roche Diagnostics, Mannheim, Germany) PCR mutation analysis was performed with the oligonucleotides listed in Table 1 . Oligonucleotides were added to LightCycler DNA Master Hybridization Probe mixture (Roche Diagnostics) in the following final concentrations: primers 0.5 mmol/L, anchor and sensor 0.2 mmol/L. The final MgCl 2 concentration was 3 mM. PCR was performed with the following temperature/time protocol: denaturation, 95°C for 1 s in the first cycle; denaturation, 95°C for 0 s in further cycles; annealing, 64°C for 12 s; elongation, 72°C for 6 s, with a transition rate of 20°C/s between temperature plateaus for a total of 50 cycles. Thereafter, melting curve analysis of amplicons was performed, starting from 45°C and proceeding until 85°C at a linear rate of 0.3°C/s. Data were analyzed by means of the LightCycler Data Analysis software (version 3; Roche Diagnostics).
K-ras
Polymerase chain reactions for K-ras exon-1 amplification were conducted using the oligonucleotide primers listed in Table 1 . The PCR was performed at 55°C for 35 cycles. Electrophoresis in a 1.5% agarose gel confirmed amplification of 150-bp DNA fragments. The PCR products were then submitted to direct sequencing, using the same primers as those described above. The resulting sequences were compared with the K-ras sequence deposited in GenBank databases.
In vitro assessment of cell proliferation and viability
To examine the effect of cetuximab on in vitro cell proliferation, 2 9 10 5 cells from the AGS, MKN-45, and NCI-N87 cell lines were seeded in six-well culture plates in 2 ml of the respective cell culture medium. The medium was changed the next day (day 1) and cetuximab was added at the following concentrations: 1, 10, and 100 lg/ml. After 72 h (day 4), the cells were trypsinized and counted in a standard hemocytometer. Cell viability was assessed by a colorimetric dye reduction assay with monotetrazolium (MTT; Boehringer, Mannheim, Germany) according to the manufacturer's instructions. Briefly, cells were seeded in 96-well plates at a density of 3 9 10 3 cells in 0.2 ml of the respective medium. Medium was changed the next day (day 1) and cetuximab was added as described above. After 72 h (day 4), 10 ll of MTT (5 mg/ml) solution, and after an additional 4 h, 100 ll of 10% sodium dodecylsulfate (SDS) were added to the cells. The plates were allowed to stand overnight (37°C, 5% CO 2 ). The change in absorbance measured at 550 nm with a microplate reader (Biotek Instruments, Burlington, VT, USA) has been shown to strongly correlate with the number of viable cells. In a second approach, the three human gastric cancer cell lines were exposed to the cytostatic agents carboplatin (30, 300, and 3000 lg/ml), irinotecan (10, 100, and 1000 lg/ml), and docetaxel (3, 30, and 300 lg/ml). Proliferation and cell viability was measured as described above. All experiments were performed in triplicates.
Laboratory animals and orthotopic implantation technique
A previously established nude mouse model for human gastric cancer [19] was employed for in vivo studies. Fourweek-old male CD-1 nude mice (CD-1/nu-nu) weighing 20-30 g were obtained from Charles River Laboratories (Sulzfeld, Germany) and were cared for in accordance with the standards of the German Council on Animal Care, under an approved protocol of the local Animal Welfare Committee. The animals were housed in type IV cages with food and water available ad libitum. Donor nude mice were anesthetized with isoflurane (Forene; Abbott, Wiesbaden, Germany) inhalation. Then 5 9 10 7 cells of the MKN-45 or NCI-N87 human gastric cancer cell lines were injected subcutaneously into the animals' flanks. Mice were sacrificed after 4 weeks (when the subcutaneous tumors had reached a size of 1 cm in largest diameter) by inhalation of isoflurane, followed by opening of the thorax and removal of the heart. The donor tumors were harvested under strict aseptic conditions and minced with a scalpel (no. 11) into small (1-mm 3 ) fragments. To avoid necrotic tissue from central tumor areas, only macroscopically viable tumor tissue from the outer part of the donor tumors was used for orthotopic implantation.
Tumor recipient nude mice were anesthetized with an intraperitoneal injection of xylazine hydrochloride (Rompun, 12 mg/kg body weight [BW]; Bayer, Leverkusen, Germany) and esketamine hydrochloride (Ketanest S, 40 mg/kg BW; Parke-Davis/Pfizer, Karlsruhe, Germany). The animals' abdomens were opened by a midline incision under aseptic conditions and the stomach was gently exteriorized. One small tissue pocket was prepared in the submucosa of the distal stomach using microscissors (RS-5610 VANNAS; Roboz, Rockville, MD, USA). One donor tumor fragment was placed into the gastric tissue pocket and fixed with one drop of tissue adhesive (Histoacryl; B. Braun, Tuttlingen, Germany). The stomach was relocated into the abdominal cavity, which was then closed in 2 layers with 4-0 absorbable suture (Ethicon, Norderstedt, Germany).
For pain relief, a subcutaneous injection of carprofen (Rimadyl Ò ; 4 mg/kg BW; Pfizer) was given after surgery.
In vivo treatment with cetuximab and carboplatin
The animals were allocated randomly to three treatment groups and a control group (12 animals per group). Treatment began 4 weeks after tumor implantation, using the following drug doses and treatment schedules-group 1: cetuximab 1 mg/animal, i.p. once a week; group 2: carboplatin 20 mg/kg body weight, i.p. once a week; group 3: cetuximab (1 mg/animal) and carboplatin (20 mg/kg), i.p. once a week; group 4: control mice were treated with 0.9% saline, i.p. once a week. The mice were monitored daily to evaluate their clinical conditions. Observation period, assessment of primary tumor size, and dissemination score Fourteen weeks after transplantation, the animals were sacrificed and an autopsy was performed to examine the growth of the tumors. The perpendicular diameters of the primary orthotopic tumor were measured with calipers, and the volume was calculated using the following formula: volume = length 9 width 9 depth/2. A dissemination score was used to assess local tumor infiltration as well as distant metastasis [20] . Local infiltration was determined at the following sites: liver, pancreas, mesentery, bowel loops, and abdominal wall. Isolated tumor nodules with no anatomic connection to the primary tumor were judged as distant metastases. Tumor dissemination was quantified as follows: every manifestation of tumor infiltration or metastasis was given one point. Additional points were given for massive local infiltration (e.g., including more than half of the circumference of the pancreas), multiple metastatic nodules ([1 in parenchymal organs; [10 on diaphragm, mesentery, retroperitoneum), and metastatic nodules [50 mm 3 . The clinical consequences of the tumor growth (formation of ascites [2 points if volume [5 ml], and the development of jaundice, ileus, and cachexia) were incorporated into this scoring system The primary tumor and all sites of potential infiltration or metastasis were harvested, fixed in 4% formaldehyde, and embedded in paraffin. Then 3-lm-thick tissue sections were obtained and stained with hematoxylin and eosin for microscopic examination. The sections were reviewed to confirm the findings of the macroscopic dissemination score.
Immunohistochemistry
Immunohistochemical staining was performed on paraffinembedded tissue. Three-micrometer-thick sections were cut, using a rotation microtome (Leica, Nussloch, Germany, RM2125RT;). The sections were deparaffinized in xylene and rehydrated in graded alcohols and distilled water. After antigen retrieval with 0.01% EDTA pH 8.0, endogenous peroxidase activity was blocked with 1% hydrogen peroxide in distilled water for 25 min, followed by washing with distilled water and finally washing with PBS ? 0.1% Tween for 5 min. To bind nonspecific antigens, the sections were incubated with 19 Power Block (BioGenex, San Ramon, CA, USA) for 5 min. The primary antibodies, EGFR (polyclonal rabbit), and CD31 (polyclonal goat), were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody dilution was 1:100 (EGFR), and 1:150 (CD31) in antibody dilution buffer (DCS LabLine, Hamburg, Germany) for 30 min at 37°C. As a negative control, sections were incubated with antibody dilution buffer instead of the primary antibody. This was followed by incubation with biotinylated antirabbit or anti-goat immunoglobulin G (1:200, Santa Cruz) for 30 min at 37°C and peroxidase-conjugated avidinbiotin complexes (KPL, Gaithersburg, MD, USA) and 3,3 0 -diaminobenzidine (Sigma-Aldrich). The sections were then Cetuximab in human gastric cancer cells 255 counterstained with Mayer's hematoxylin, upgraded alcohols, mounted, and analyzed by standard light microscopy. Immunostaining assessment for EGFR was performed regarding the staining intensity, using a fourpoint scale (0 = negative, ? = weak, ?? = moderate, ??? = strong).
Microvessel density was quantified as described by Weidner [21] . Areas of highest neovascularization were found by scanning the sections at a magnification of 1009; individual microvessel counts were then made on fields at 2009 magnification (&0.74 mm 2 per field).
Statistical analysis
Data are presented as means ± SEM. Continuous, normally distributed variables were analyzed by Student's t-test. Discontinuous variables (dissemination score) were analyzed by the Mann-Whitney rank sum test. The survival data were analyzed by Kaplan-Meier test, and the survival periods were compared by the log-rank test. Differences were considered statistically significant at a p value of\0.05.
Results
EGFR mRNA and surface expression in tumor cell lines
All three gastric cancer cell lines were evaluated to obtain the baseline levels of EGFR. As shown by RT-PCR, all three cell lines expressed EGFR at the mRNA level (Fig. 1a) , whereas FACS analysis revealed different levels of cell surface EGFR expression in the gastric cancer cell lines (Fig. 1b) . In AGS we detected two cell populations, one positive for EGFR and one negative. The cell line MKN-45 was negative for EGFR cell surface expression and all NCI-N87 cells showed surface expression of EGFR. Immunohistochemical analysis of tumor xenografts confirmed membrane EGFR expression on NCI-N87 cells in vivo (Fig. 1d) . However, corresponding to the mRNA expression, the cell line MKN-45, which was negative for cell surface EGFR, revealed weak cytoplasmic staining.
BRAF and K-ras mutation analysis
All three cell lines AGS, MKN-45, and NCI-N87 were tested for the presence of point mutations in BRAF (exon 15, codon 600, p.V600E GTG ? GAG, p.V600K GTG ? AAG, p.600R GTG ? AGG) by melting curve analysis, and the presence of point mutations in K-ras (exon 1, codons 12 and 13) was tested by direct sequencing. No BRAF point mutation was found in any of the cell lines. A K-ras point mutation was found only in the cell line AGS (GGT ? GAT at codon 12, Gly ? Asp). MKN-45 and N87 displayed no K-ras mutations at codons 12 or 13.
Effects of cetuximab, carboplatin, irinotecan, and docetaxel on cell viability and proliferation in vitro
The effects of cetuximab and the chemotherapeutic agents carboplatin, irinotecan, and docetaxel on the viability and proliferation of the human gastric cancer cell lines AGS, MKN-45, and NCI-N87 were studied over a time period of 72 h. Figure 2 shows the proliferation and viability changes during drug treatment. For statistical calculations, untreated control cells were set at 100% viability and proliferation. Cetuximab at concentrations from 1 to 10 lg/ ml was neither cytotoxic nor cytostatic. Only the cell line NCI-N87 showed decreased proliferation (62.9%) at 10 lg/ ml cetuximab. Higher concentrations, up to 100 lg/ml, reduced cell viability significantly in all three cell lines (AGS 81.8%, MKN-45 83.8%, NCI-N87 88.7%). While proliferation was reduced to 79.9% in MKN-45 cells and to 52.8% in NCI-N87 cells, the proliferation of AGS cells was not affected by cetuximab even at the highest concentration (100 lg/ml) (Fig. 2a) . The chemotherapeutic agents carboplatin, irinotecan, and docetaxel significantly inhibited cell viability and proliferation in all the gastric cancer cell lines in a dosedependent manner (Fig. 2b-d 
Tumor growth and dissemination
For the in vivo experiments in mice, we examined the antitumor effects of cetuximab and carboplatin in the human K-ras wild-type gastric cancer cell lines MKN-45 (negative for EGFR cell surface expression) and NCI-N87 (positive for EGFR cell surface expression). The tumor take rate after the implantation of viable donor tumor fragments into the distal stomach was 100% for both cell lines. Dislocation of tumor fragments from the orthotopic implantation site was not observed.
Tumor volume
The volume of tumors derived from the poorly differentiated MKN-45 cell line during the observation period is shown in Fig. 3a , with a mean tumor volume of 655.9 ± 330.2 mm 3 in the control group. In vivo treatment with either cetuximab, carboplatin, or the combination of both agents did not reduce the volumes of orthotopic gastric MKN-45 cancers (608.4 ± 241.5, 699.5 ± 231.1, and 783.1 ± 393.2 mm 3 , respectively). Implanted NCI-N87 tumor fragments grew to well-differentiated adenocarcinomas with a mean tumor volume of 1125 ± 448.6 mm 3 in control animals (Fig. 3b) . Cetuximab reduced the tumor volume to 453.4 ± 286.6 mm 
Dissemination
Local infiltration to adjacent structures and metastatic spread into distant organs resulted in an average dissemination score of 5.82 ± 2.27 points in MKN-45 control animals, 4.08 ± 1.52 points in animals treated with cetuximab, 5.56 ± 1.88 points in the carboplatin group, and 7.45 ± 2.53 points in animals that received cetuximab and carboplatin (Fig. 3) . Local infiltration occurred predominantly to the liver and the pancreas. Distant metastasis to the lung was found in 17% of MKN-45 control animals, 17% of the cetuximab group, 25% of the carboplatin group, and 50% of the animals which received cetuximab ? carboplatin. Affected lymph nodes in the liver hilum were seen in 42% of control animals, in 33% of the cetuximab group, 58% of the carboplatin group, and 42% of the cetuximab ? carboplatin group. No treatment strategy resulted in a significant reduction of tumor dissemination in this cell line.
In contrast, NCI-N87 tumor-bearing mice showed a dissemination score of 11.78 ± 4.55 points in the control group, 8.55 ± 4.96 points in the cetuximab group, 7.17 ± 3.33 points after treatment with carboplatin, and 4.36 ± 2.53 points in the combination group (cetuximab ? carboplatin; p \ 0.05 vs. controls; Fig. 3 ). Distant metastatic spread to the lung was seen in 50% of control animals, in 33% of animals treated with cetuximab, in 42% of animals in the carboplatin group, and in only 17% of animals treated with cetuximab and carboplatin.
Survival
As shown in Fig. 4 , tumors derived from the MKN-45 cell line grew and spread less aggressively; 75% of the control animals survived within the observation period. Treatment with cetuximab resulted in a 14-week survival of 92%, while 58% of the animals in the carboplatin group and 50% of the animals in the combination group were alive at the end of the study. The aggressive in vivo behavior of NCI-N87 tumors was associated with a low 14-week survival in the control group (25%). Cetuximab and carboplatin increased survival to 50%, and the combination of both agents led to a 33% survival. These differences between the two tumor types were not statistically significant.
Microvessel density in vivo after EGFR blockade
The MVD as a parameter of angiogenic activity was determined by immunohistochemistry, using anti-CD31 as an endothelial marker (Fig. 5a) . In MKN-45 tumors, the mean MVD was unchanged in all groups (control 54. 13 (Fig. 5b) . 
Discussion
Recently, Bang et al. [22] reported the first phase 3 trial that demonstrated a significant therapeutic effect of targeted antibody therapy for gastric cancer: a combination of trastuzumab, a monoclonal antibody against EGFR2 (HER2), and chemotherapy was able to prolong survival when compared to chemotherapy alone in cancers overexpressing HER2. As in breast cancer, the expression of HER2 was a prerequisite for the preclinical as well as clinical efficacy of HER2 targeting. Several agents have been developed for targeting EGFR, including monoclonal antibodies and thyrosine kinase inhibitors. One of these antibodies, cetuximab, exerts its antitumor efficacy by multiple mechanisms that include the inhibition of cell cycle progression by arrest in the G1-phase and decreased cell number in the S-phase. Cell cycle arrest in the G1-phase also induces apoptosis by the induction and activation of proapoptotic molecules [23] . Cetuximab was approved for the treatment of patients with advanced colorectal cancer and also for the treatment of squamous cell carcinoma of the head and neck. In addition, cetuximab has been investigated in multiple phase II and III studies in unselected patients with lung, gastric, esophageal, and pancreatic cancer [24] [25] [26] . However, only a subset of patients responded to cetuximab. In all of the carcinomas investigated, the efficacy of cetuximab was not associated with the EGFR cell surface expression levels detected by immunohistochemistry. In patients with colorectal carcinoma, however, intrinsic activation of the EGFR signaling pathway by activating mutations of K-ras or BRAF was recently identified as a marker for patient selection, as K-ras and BRAF mutations were associated with complete inefficacy of cetuximab treatment [16] . On the other hand, more recent data suggestthat the BRAF mutation status is not a strong predictive biomarker for cetuximab activity [27] and should therefore not be used as a selection factor for treatment with EGFR-targeted agents in patients with wild-type K-ras tumors.
There are currently ongoing clinical trial programs of EGFR targeting in unselected patients with gastric cancer, but, to our knowledge, the relationship of cetuximab efficacy to cell surface EGFR expression and mutational status has not been sufficiently tested in preclinical models. The anti-tumor effects and mechanisms of cetuximab have already been described in xenograft models of gastric cancer [28, 29] , but the present study is the first to have employed an orthotopic animal model of gastric cancer which recapitulates not only local tumor growth but also the process of metastasis. We here initially investigated 3 cell lines, but later excluded the AGS cell line from in vivo testing because of its heterogeneity for EGFR expression and presence of mutated K-ras. Thus, we report here on two cell lines with an interesting phenotype, both wild-type K-ras and BRAF, with NCI-N87 expressing EGFR on the surface, in contrast to MKN-45, which lacks cell surface EGFR expression, but which shows the presence of EGFR transcripts at the mRNA level and also shows cytoplasmic antibody staining. Carboplatin was preferred for combination therapy over cisplatin, due to personal experience with the drug in animal studies and because carboplatin has been described as a second-generation analogue of cisplatin with less nephro-, neuro-, and ototoxicity, while it is at least as active as cisplatin at its maximum tolerated dose [30, 31] .
While the cell line MKN-45 was slightly sensitive to cetuximab in vitro at the highest concentration of 100 lg/ ml, as well as being responsive to carboplatin, in vivo findings showed that tumors originating from these cells were completely resistant to cetuximab and carboplatin either alone or in combination, suggesting that the cytoplasmic expression of the EGFR was irrelevant for the in vivo efficacy of EGFR targeting. Such a discordance between the in vitro and in vivo activities of cetuximab has previously been reported in preclinical studies of other tumor types, such as colorectal cancer and thyroid cancer [14, 32] . The EGFR-positive cell line NCI-N87, however, responded to cetuximab as well as carboplatin in vitro and in vivo, with evidence for in vivo synergy between both agents. These results are consistent with other studies demonstrating that the antitumor activity of several anticancer agents increases when combined with cetuximab [5, 9, 25, 32] .
In addition to the primary efficacy observation, we also observed that treatment with cetuximab significantly reduced MVD in the EGFR-positive NCI-N87 tumors but not in the EGFR-negative MKN-45 tumors. In contrast, carboplatin alone was found to reduce tumor growth, but not MVD, in NCI-N87 tumors, and combination treatment led to a further reduction of the tumor volume, but had no additional effect on MVD, indicating that the antiangiogenic impact is exerted by cetuximab and not by carboplatin. It has previously been described that the vascular endothelial growth factor (VEGF) and EGFR pathways are closely related in solid tumors, as EGF signaling is able to induce VEGF expression. Blockade of EGFR with cetuximab resulted in the downregulation of proangiogenic mediators, including VEGF, accompanied by reductions in MVD and metastases in tumor xenografts of transitional cell carcinoma, colorectal cancer, and thyroid carcinoma [18, 32, 33] .
In conclusion, the present report has demonstrated that therapy with cetuximab alone and in synergy with carboplatin resulted in decreases of tumor size, metastatic spread, and MVD in NCI-N87 tumors with EGFR cell surface expression and absence of mutations in BRAF and K-ras, whereas cetuximab had minimal in vitro effect and no in vivo treatment efficacy in tumors derived from MKN-45, in which the phenotype was also BRAF and K-ras wildtype, but which had only weak cytoplasmic EGFR protein expression. Further, there was no in vitro effect on AGS cells displaying mutated K-ras. These results suggest that patient selection based on K-ras mutation as well as EGFR surface expression could prove useful in clinical trial programs with EGFR targeting in patients with gastric cancer. 
